Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter,Open-label,Phase II Clinical Trial to Evaluate the Efficacy and Safety of Niraparib + Aromatase Inhibitors for(HR)+/(HER2)-, MBC With Either Germline BRCA-mutated or Germinal BRCA-wildtype and Homologous Recombination Deficiency

NCT04240106 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT04240106
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04240106 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter,Open-label,Phase II Clinical Trial to Evaluate the Efficacy and Safety of Niraparib + Aromatase Inhibitors for(HR)+/(HER2)-, MBC With Either Germline BRCA-mutated or Germinal BRCA-wildtype and Homologous Recombination Deficiency
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Completed
Start date
June 15, 2020
Completion date
November 17, 2023
Enrollment
14 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast cancer metastatic